Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
PMV PharmaceuticalsEli Lilly
Last price
$1.39$1,421.30
Currency
USD
USD
$103M$1.3T
-46.01
-$1.41$30.81
1.350.45
0$6.69
00.49%
Sector
HealthHealth
Employees
5450,000
Ticker
$PMVP$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $PMVP or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.